22UA:FRA
BioNTech SE - ADR
€ 79.95
arrow_upward
+0.19%(+0.15) 1D
10-р сарын 14, 10:57:13 (GMT+2) · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€ 79.65
High
€ 80.55
Low
€ 79.55
Mkt. cap
22.36 тэрбум
Avg. vol.
1.30 мян
Volume
680.00
52-wk high
€ 105.50
52-wk low
€ 68.00
No. of employees
8 мян
Open
€ 79.65
High
€ 80.55
Low
€ 79.55
Mkt. cap
22.36 тэрбум
Avg. vol.
1.30 мян
Volume
680.00
52-wk high
€ 105.50
52-wk low
€ 68.00
No. of employees
8 мян
News stories
From web sources and news partners
TradingKey
·
16 цагийн өмнө
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
GuruFocus
·
20 цагийн өмнө
BioNTech (BNTX) Shares Slide After BNT113 Vaccine Misses Progres
BioSpace
·
21 цагийн өмнө
BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
The Globe and Mail
·
23 цагийн өмнө
BMO Capital Reaffirms Their Hold Rating on BioNTech SE (BNTX)
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR